The welfare costs of HIV/AIDS in eastern Europe: an empirical assessment using the economic value-of-life approach

Eur J Health Econ. 2010 Jun;11(3):305-22. doi: 10.1007/s10198-009-0177-y. Epub 2009 Aug 5.

Abstract

Based on the aggregation of individual willingness-to-pay for a statistical life, we calibrate an inter-temporal optimisation model to determine the aggregate welfare loss from HIV/AIDS in 25 Eastern European countries. Assuming a discount rate of 3%, we find a total welfare loss for the whole region that exceeds US $800 billion, approximately 10% of the region's annual GDP between 1995 and 2001. Although prevalence and incidence rates diverge sharply between countries-with central Europe far less affected than major countries in the Commonwealth of Independent States and the Baltics-the epidemic is likely to spread to all countries unless a coherent strategy of prevention and treatment is backed up by substantial increases in healthcare investments. The sheer size of this task and the international nature of the epidemic render this one of the most important current challenges for all of Europe.

MeSH terms

  • Acquired Immunodeficiency Syndrome / economics*
  • Acquired Immunodeficiency Syndrome / mortality*
  • Adult
  • Calibration
  • Cost of Illness*
  • Cost-Benefit Analysis
  • Economics
  • Europe, Eastern / epidemiology
  • HIV Infections / economics*
  • HIV Infections / mortality*
  • Humans
  • Incidence
  • Income
  • Life Expectancy
  • Middle Aged
  • Models, Econometric
  • Prevalence
  • Value of Life / economics*